TOTAL: $599.3M

Company
(Location)

Type Of
Financing

Number Of
Shares, Units
Or Warrants
(M)

Amount
Raised
(M)

Investors; Placement Agents; Details

Date

Ablynx NV (Ghent, Belgium)

Private placement of new shares

4.38S

€31.5 ($40.9)

Ablynx raised $40.9M through a private placement of new shares via an accelerated book-building procedure

3/4/13

Active Biotech AB (Lund, Sweden)

Private placement

6S

SEK270 ($42.6)

Active Biotech raised $42.6M by issuing 6M shares to Investor AB

3/8/13

Bionomics Ltd. (Adelaide, Australia)

Rights issue

N/A

A$16.4 ($16.86)

Bionomics reported a 1-for-8 non-renounceable rights issue at A$0.36 per new share to raise up to about A$16.4M; the offer is underwritten by Bell Potter Securities ltd.

3/5/13

BioTime Inc. (Alameda, Calif.)

Stock and warrant purchase agreement

N/A

$5

BioTime is receiving $5M through the agreement with Romulus Films Ltd.

3/8/13

Cell Therapeutics Inc. (Seattle)

Loan

N/A

$10

Cell Therapeutics entered an agreement for a senior secured term loan up to $15M with Hercules Technology Growth Capital Inc.; the first $10M of the loan was funded at closing, and the remaining $5M will be available Nov. 30, 2013, to Dec. 15, 2013

3/29/13

CombiMatrix Corp. (Irvine, Calif.)

Private placement of common stock and units

0.13S and 0.00162U

$2

CombiMatrix issued 130,000 shares at $3.05 per share and about 1,610 units at $1,000 each to an existing institutional investor

3/21/13

DelMar Pharmaceuticals Inc. (Vancouver, British Columbia)

Private placement of units

13.09U

$10.5

DelMar completed a $10.5M private placement of units consisting of one share of common stock and one common stock purchase warrant; the offering consisted of 9.34M units for $7.5M and a fully exercised overallotment option of 3.75M units for $3M

3/8/13

Durata Therapeutics Inc. (Chicago)

Debt facility

N/A

$20

Durata is receiving $20M through a debt facility with Oxford Finance LLC

3/11/13

EntreMed Inc. (Rockville, Md.)

Registered direct offering

4.5S and W for 2.25S

$10.7

EntreMed received commitments from investors to purchase $10.7M of securities in a registered direct offering

3/4/13

Evolva Holding SA (Reinach, Switzerland)

Private placement

52.2S

CHF31.3 ($32.8)

Evolva completed its capital raise, which was fully subscribed by existing shareholders and new investors for gross proceeds of $32.8M; the raise consisted of a rights offering of 52.2M shares to existing shareholders who took up about 24.2M of the shares; the remaining 28M were placed with Cargill Inc. and a group of institutional investors

3/28/13

Immunovaccine Inc. (Halifax, Nova Scotia)

Private placement

4.8S

$1.6

Immunovaccine received one common share at a price of C33 cents (32 cents), issuing 4.8M common shares

3/1/13

Innovus Pharmaceuticals Inc. (La Jolla, Calif.)

Funding commitment

N/A

$0.5

Innovus received a $500,000 funding commitment by its president and CEO, Bassam Damaj

3/21/13

International Stem Cell Corp. (Carlsbad, Calif.)

Private placement

N/A

$1

International Stem Cell raised $1M from a number of existing longstanding investors through a private placement

3/15/13

Mesoblast Ltd. (Melbourne, Australia)

Private placement

N/A

A$170 ($174.6)

Mesoblast raised $174.6M in a private placement

3/8/13

Neuralstem Inc. (Rockville, Md.)

Debt financing

N/A

$8

Neuralstem secured $8M in debt financing with Hercules Technology Growth Capital

3/26/13

OvaScience Inc. (Cambridge, Mass.)

Private placement

N/A

$35

OvaScience raised $35M in a placement with certain investors including Adage Capital Management, Deerfield Management Co., EcoR1 Capital Fund and Jennison Associates LLC

3/14/13

Prana Biotechnology Ltd. (Melbourne, Australia)

Private placement

35.9

A$7 ($7.3)

Prana secured funding of $7.3M through a placement of about 35.9M fully paid ordinary shares priced at A19.5 cents per share

3/28/13

PTC Therapeutics Inc. (South Plainfield, N.J.)

Private placement

N/A

$60

PTC raised $60M in a financing led by Brookside Capital Partners Fund LP; other investors were Adage Capital Management, Jennison Associates LLC, Longwood Fund, and some institutional investors; Credit Suisse First Boston, HBM Healthcare Investments Ltd., Vulcan Capital, Celgene, Delphi Ventures, Novo A/S and the Column Group also participated

3/8/13

Resverlogix Corp. (Calgary, Alberta)

Loan agreement

N/A

$38.8

Resverlogix amended and restated a loan agreement with Citibank NA, increasing the loan to $38.8M

3/12/13

Rockwell Medical Inc. (Wixom, Mich.)

Registered direct offering

4.3S

$12.9

Rockwell is selling 4.3M common shares at $3 each to raise $12.9M; Chardan Capital Markets LLC was the lead placement agent, and Newbridge Securities LLC was the co-placement agent

3/21/13

RXi Pharmaceuticals Corp. (Westborough, Mass.)

Private placement

113S

$16.4

RXi raised $16.4M in a private placement led by OPKO Health Inc. and Frost Gamma Investments Trust; other investors were Tang Capital Partners LP and RTW Investments LLC, as well as new institutional and accredited investors

3/8/13

Sirona Biochem Corp. (Vancouver, British Columbia)

Private placement of units

14.245U

$1.43

Sirona completed the sale of 14.245M units at $0.10 per unit for $1.43M in the first tranche of a private placement

3/8/13

Uluru Inc. (Addison, Texas)

Private placement

1.1S and W for 0.66S

$0.44

Uluru completed an agreement to sell an aggregate of 1.1M shares of common stock priced at 40 cents apiece, resulting in $440,000; investors were Kerry P. Gray and Terrance K. Wallberg, who also receive warrants to purchase up to 660,000 shares

3/18/13

Vivus Inc. (Mountain View, Calif.)

Synthetic capped royalty financing

N/A

$50

Vivus will make an initial draw of $50M and, at its discretion, draw another $60M any time prior to Dec. 31; the payments are subject to a capped percentage of future net sales of obesity drug Qsymia, and the financing is being executed through an investment fund managed by Pharmakon Advisors

3/27/13

Notes:

This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Loan money is included in the total only when it is drawn down, if disclosed.

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

N/A = Not applicable; ND = Not disclosed.